Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

Take SHPT treatment in a different direction

Rayaldee® is the first and only extended-release prohormone of the active form of vitamin D3 that brings 25-hydroxy vitamin D levels up, iPTH levels down, with the effects on calcium and phosphorus similar to placebo.

25D
iPTH

CA/P Similar to placebo*

*Calcium: Rayaldee 0.2 (0.02) mg/dL versus placebo 0.1 (0.03) mg/dL (P<0.001);
Phosphorus: Rayaldee 0.2 (0.03) mg/dL versus placebo 0.1 (0.04) mg/dL1